Publication at Third Faculty of Medicine |
2018
Abstract
High-risk and locally advanced prostate cancers constitute a relatively heterogeneous group of diseases with varying prognosis. Multimodal therapy is more effective than monotherapy.
A combination of radiotherapy and androgen deprivation therapy is the gold standard. Dose-escalated radiotherapy using the technique of intensity-modulated radiotherapy and that of image-guided radiotherapy is recommended.
In recent years, new data supporting radiation dose escalation using a combination of external radiotherapy and brachytherapy have become available. Research is also focused on adding chemotherapy or novel antiandrogen drugs to standard androgen deprivation therapy and radiotherapy.